Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03107091
Other study ID # CIT-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 15, 2017
Est. completion date April 25, 2019

Study information

Verified date April 2019
Source BioVie Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.


Description:

Terlipressin continuous infusion will be adminstered via an ambulatory pump initially for 7 days in a clinical pharmacology unit. Serial blood draws for pharmacokinetic analysis will be performed to determine steady state concentration of both terlipressin and 8-lysine-vasopressin during infusion. After establishing safety and tolerance of infusion for 7 days, patients will be transitioned to an outpatient setting where they will be treated with terlipressin continuous infusion for an additional 21 days, monitored daily by home care nurses. A total of 6 patients will be treated. Monitoring will include successful management of ascites, with reduction in paracentesis procedures and decreased ascites fluid volume, further supported by improvement in renal function.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date April 25, 2019
Est. primary completion date April 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients with cirrhosis and refractory ascites who required 3 or more large volume (4 liters and more) paracenteses in the previous 60 days Exclusion Criteria: - Ascites with causes other than cirrhosis such as nephrogenic ascites or malignant ascites due to peritoneal carcinomatosis - Total bilirubin > 5 mg/dL - Blood clotting International normalized ratio (INR) > 2.5 - Serum creatinine > 2.0 mg/dL - Current or recent (within 3 months of consent) renal dialysis - Hepatic encephalopathy grade 3 or 4 - Superimposed acute liver failure/injury due to factors other than alcoholic hepatitis, including acute viral hepatitis, drugs, medications (e.g., acetaminophen), or other toxins (e.g., mushroom [Amanita] poisoning) - Current or recent treatment (within 7 days) with octreotide, midodrine, vasopressin, dopamine or other vasopressors - Respiratory failure requiring positive airway pressure devices or intubation - SIRS/sepsis episode in the previous 28 days from consent - Episode of spontaneous bacterial peritonitis or gastrointestinal hemorrhage within 28 days of consent - Ongoing documented or suspected infection - Severe cardiovascular disease that are contraindication to terlipressin therapy such as advanced arteriosclerosis, arrhythmia, coronary insufficiency or uncontrolled hypertension - Findings suggestive of organic renal disease (severe proteinuria/hematuria, or abnormal renal ultrasound suggestive of obstructive or other renal pathology) - Severe comorbidity that in the opinion of the Investigator would affect short-term prognosis and/or disallow safe participation in the trial (such as for example, severe anemia or pancytopenia, advanced neoplasia, hepatocellular carcinoma [confirmed with serum alpha1-fetoprotein testing], severe chronic obstructive pulmonary disease or asthma) - Alcoholics who have not been abstinent for the past 6 months - Transjugular intrahepatic portosystemic shunt or other surgical shunt - For female patients: Confirmed pregnancy - Known allergy or hypersensitivity to terlipressin - Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Terlipressin acetate continuous infusion
Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days

Locations

Country Name City State
United States Hunter Holmes McGuire VA Medical Center Richmond Virginia

Sponsors (1)

Lead Sponsor Collaborator
BioVie Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites Rate of treatment emergent adverse events assessed by physical examination and laboratory safety 28 day treatment period and 28 day post-treatment
Primary Steady State Plasma Levels of Terlipressin and 8-lysine Vasopressin During Terlipressin Continuous Infusion at 2 mg/Day in Cirrhotic Patients With Refractory Ascites Serial sampling for determination of Terlipressin concentration and metabolite 8-lysine vasopressin in plasma at steady state (Css) 7 day treatment
Secondary Change in Requirement of Large Volume Paracentesis With Continuous Infusion of Terlipressin Comparison of pre-treatment and post-treatment incidence of therapeutic paracentesis and change in volume of ascites removed 28 day post-treatment
See also
  Status Clinical Trial Phase
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05014594 - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT Phase 2
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT04939350 - Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Completed NCT02528760 - To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis N/A
Recruiting NCT05484206 - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Phase 1
Not yet recruiting NCT05538546 - Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Recruiting NCT02983968 - Use of the French Healthcare Insurance Database
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02596880 - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics Phase 3
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Withdrawn NCT01956864 - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer Phase 1
Completed NCT02016196 - Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS Phase 3
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed NCT02113631 - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir N/A
Completed NCT01447537 - Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis N/A
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01231828 - Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. N/A